
Study Points to Promising Chemoimmunotherapy Strategy for Aggressive Stage III Non-Small Cell Lung Cancer
Study Title: Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer Publication: JAMA Oncology Corresponding Dana-Farber Cancer Institute authors: Biagio Ricciuti, MD, PhD …